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Abstract   
 
Background: Mental Health Conditions including Major Depressive Disorders cause 
many emergency department visits and hospital admissions with few acute treatment 
options. The use of N-methyl-D-aspartate antagonist drugs such as Ketamine show 
promise in treatment of these patients.  
 
Method:  Exhaustive search of medical literature using MEDLINE, CINAHL, 
PsychInfo, and EBM multifiles was conducted, using search terms Ketamine, Major 
Depressive Disorder, N-methyl-D-aspartate Antagonist, Excitatory Amino Acid 
Antagonist. Articles that were not randomized control trials or were duplicates were 
excluded.   
 
Results: Two studies fit inclusion, exclusion criteria. The studies found were of low 
quality using the GRADE approach. Patients that received Ketamine when compared to 
placebo were found to have a decrease in depressive symptoms.  
 
Conclusion: The current research shows a connection between N-methyl-D-aspartate 
antagonists like Ketamine and decrease depressive symptoms. Although due to the low 
quality of the studies the use of Ketamine in treating Major Depressive Disorders should 
not be adopted without further examination.  
 
Keywords:  Ketamine, Major Depressive Disorder, N-methyl-D-aspartate Antagonist, 
Excitatory Amino Acid Antagonist.    
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The Use of Ketamine to Decrease Depressive Symptoms in Adults With 
Major Depressive Disorder 
 
BACKGROUND 
 In 2007 there were 4.1 million visits to the Emergency Department that listed a 
mental health condition as their primary diagnosis of which 41% resulted in the patient 
being admitted.1 When a patient is seen in the ED with depressive symptoms, it often 
requires admission to allow for time for medication to take effect. With the number of 
patients being seen in the ED for mental health issues on the rise over the past decade,2 
the need for a fast acting, effective antidepressant is quickly becoming apparent.  
 The pathophysiology of depression is widely accepted as a regional reduction in 
brain volume, although the precise etiology is still not fully understood. Current 
antidepressant therapy works by increasing synaptic serotonin or norepinephrine, which 
can take weeks or months to work. The delayed response is suggestive of a cascade 
effect. A growing body of data points to the glutamatergic modulating system as a 
proximal player in the suspected pathway to neuronal plasticity and cellular resilience, 
thought to be directly correlated with severe mood disorders. 3,4   
In addition to the decreased time to onset of therapy, the glutamatergic 
modulating system shows promise in treating refractory patients. Current antidepressant 
therapies, such as the popular SSRIs, have a better side effect profile when compared to 
older medications, but have changed very little in their mechanism of action. This raises 
concern about our current therapy as there is a large population of patients that are 
refractory to these medications. Finding a medication that works more proximally in the 
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chain of biochemical events leading to depression, may help this subpopulation of 
depressed patients suffering from prolonged illness.3 
Glutamate is an excitatory neurotransmitter that regulates many different 
activities of the central nervous system (CNS), and has a crucial role in many aspects of 
normal brain function. Glutamate, a mainly intracellular neurotransmitter, is released into 
the synaptic cleft, and binds to one of the 3 identified receptors: N-methyl-D-aspartate 
(NMDA) , AMPA/kainite, or the metabotropic receptor. Among their many functions, 
activation of these receptors is responsible for brain cell production, elimination, and 
differentiation, along with proliferation and destruction of neuronal communication. 
Following the interaction of the chemical receptor, excess extracellular glutamate binds 
to, the glutamate uptake pump, and is transported back into the cell. To assure the 
maintenance of low extracellular glutamate, astroglial cells patrol the extracellular fluid 
converting excess glutamate to inactive glutamine.4-6 Increased extracellular glutamate 
causes inflammation at the amygdala, the area of the brain that controls fear and anger, 
reducing its control. The act of internalizing these excess feelings of fear and anger is 
thought to lead to depression.7  
A proposed theory behind the use of Ketamine is that blocking glutamate at the 
NMDA receptor will decrease dysfunction in brain plasticity.7,8 This review addresses the 
efficacy of Ketamine in decreasing symptoms in adult patients with Major Depressive 
Disorder.  
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METHODS 
Data Search 
 A systematic search of electronic databases, and bibliographies was conducted to 
find all studies that discuss the use of N-methyl-D-aspartate antagonists in Major 
Depressive Disorders. MEDLINE, CINAHL, and PsychInfo were the databases used in 
the comprehensive search. A methodical approach of combining Mesh terms was used to 
elicit the most pertinent articles. Mesh terms included: Major Depressive Disorder and 
N-methyl-D-aspartate antagonists or Excitatory Amino Acid Antagonist or Ketamine or 
Memantine. The bibliographies of all studies obtained were then searched for eligible 
studies. All studies obtained were reviewed for relevance using preset inclusion, and 
exclusion criteria.  
 
Inclusion/Exclusion 
 All studies that looked at the use of Ketamine in decreasing depressive symptoms 
in patients with DSM IV criteria for Major Depressive Disorder were included, regardless 
of the date of the study, language, or publication status. Studies that used the Hamilton 
Rating Scale for Depression, as at least one determinant of outcome, were included.  
Studies were excluded if they were an open-label studies, or looked at NMDA antagonist 
drugs other than Ketamine in the treatment of Major Depressive Disorder.  
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Quality Assessment 
 Article that met the inclusion criteria were reviewed for validity using a 
standardized form. The articles were then analyzed using the Cochrane GRADE method, 
to assess limitations of methodology, inconsistent results, indirectness of evidence, 
publication bias, or lack of precision.9 GRADE criteria was then applied to rate the 
quality of the study as high, moderate, low, or very low.  
RESULTS 
 The systematic literature search identified 223 relevant references (Figure I). 
After screening abstracts 209 of the articles were either not relevant articles, or repeats. 
Full text articles were printed of the remaining 14 articles for formal review. After 
reviewing the 14 articles, 12 were excluded because they were open-label studies, or 
looked at other glutamate antagonists other than Ketamine. Bibliographies from the 
studies were also reviewed for relevant studies. Only 2 additional studies were found that 
were not a repeat of studies already obtained, but they did not meet inclusion/exclusion 
criteria. No more studies were added. Table I gives an outline of the 2 studies that met all 
inclusion and exclusion criteria with formal GRADE9.   
   
Zarate et al 
 This study10 enrolled 18 patients with the DSM-IV criteria for Major Depressive 
Disorder. All patients went through a 2 week drug holiday prior to starting the study. 
They were then randomly assigned to either receive 0.5mg/kg of Ketamine or placebo on 
week 1 and switched and received the opposite treatment on week 2, in a crossover 
double-blinded fashion. Patients were interviewed 60 minutes prior to the administration 
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of Ketamine or placebo and at 40, 80, 110, and 230 minutes post administration, along 
with 1,2,3 and 7 days post infusion using the Hamilton Depression Rating Scale 
(HDRS)11 as the primary endpoint. The Becks Depression Inventory (BDI),12 Brief 
Psychiatric Rating Scale (BPRS),13 and Young Mania Rating Scale (YMRS)14 were 
secondary endpoints. Response was defined by a 50% decrease in the HDRS, and 
remission was defined by a score of 7 or below. Of the 18 patients, 9 patients received 
Ketamine on week 1, but only 4 went on to receive placebo on week 2, due to “improved 
mood” from phase one. In the placebo group, 1 patient did not complete the second phase 
due to unrelated medical problems.10 
Zarate et al10 performed both an intent-to-treat analysis and an analysis of those 
actually completing both phases of treatment.  The analysis looked at the HDRS survey 
to assess drug efficacy.10  
Patients completing both phases--The mean HDRS score when looking at the Ketamine 
group versus the placebo group showed a large effect (F=58.24) with a small probability 
of a type one error (p<.001). When effects of Ketamine were examined at different time 
intervals there was a significant effect (F=9.48; p<.001). When they analyzed Ketamine 
versus placebo at the different time intervals, there was a lower effect (F=4.15), but it was 
still statistically significant (p<.001). The effect size showed a large effect size d=1.46 at 
24 hours (95% confidence interval 0.91-2.0). At 1 week the effect size was considered 
moderate d=0.68 (95% confidence interval 0.13-1.23).10 
Intent-to-treat—The intent-to-treat group had similar effects as the completers. There 
was a significant effect when analyzing the mean HDRS for  Ketamine when compared to 
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placebo (F=34.08; p<.001), Ketamine at different time intervals (F=8.92; p<.001), and 
Ketamine versus placebo across the time intervals (F=5.29;p<.001).10 
 The study10 also examined “responders” and “remitters” which are shown in 
figure 3. Of the patients treated with Ketamine 12 of the 17 had a 50% decrease in their 
HDRS11 after 24 hours, placing them in the responders category, while 5 of the 17 met 
remissions criteria with a score less than 7. Of the 12 patients who met response criteria 6 
maintained response criteria for 1 week and 2 maintained response for 2 weeks. None of 
the patients receiving placebo met response or remission criteria, at any point within the 
study.10 
The results of the secondary outcomes supported the findings of the primary 
outcome and can be examined in Figure III. BPRS positive symptoms scores show no 
correlation to the decreased depressive symptoms seen by the increased HDRS scores.   
 
Berman et al 
 The Berman et al5 study only enrolled 9 patients who fulfilled the DSM-IV 
criteria for Major Depressive Disorder. All patients had a 2 week drug holiday prior to 
the start of the study. Patients were then randomly assigned to either receive Ketamine 
0.5mg/kg or placebo on week 1 then switching, and those who received Ketamine on 
week 1 received placebo on the second week, in a double-blinded crossover fashion. Two 
patients stopped the study after the first phase, one from each group drug and placebo, to 
seek antidepressant therapy. Patients were interviewed at baseline as well at 80 minutes, 
230 minutes, 24 hours, 48 hours, and 72 hours post infusion using the Hamilton 
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Depression Rating Scale (HDRS) as a primary endpoint. Secondary endpoints included 
BDI, BPRS, and Visual Analog Scale score for intoxication.  
 The HDRS score was then analyzed on the patients completing both phases of 
treatment, examining Ketamine versus placebo, Ketamine versus time, and Ketamine 
versus placebo with respects to time. Ketamine versus placebo and Ketamine versus time 
were not statistically significant (F=0.157 p=.71; F=2.62 p=.09, respectively), but 
Ketamine versus placebo with respect to time showed statistical significance with an 
F=3.97 and p=.02. Figure IV depicts the mean change in HDRS scores from baseline.5 
 Berman et al5 had 4 of the 8 patients receiving Ketamine have a 50% or greater 
reduction in HDRS score. Only 1 of the 8 in the placebo group had that large a decrease 
in score. Patient’s scores all returned to baseline +/- 5 points within 1-2 weeks of 
Ketamine infusion. BPRS scores were also analyzed, but were not statistically significant 
and did not correlate with the HDRS scores.5 
Adverse events 
 The most significant adverse event seen with the use of Ketamine was a feeling of 
euphoria, confusion, perceptual disturbances, elevated blood pressure, dizziness, and 
increased libido. The Zarate et al10 study showed a significant worsening of BPRS scores 
in the Ketamine group over the placebo group at 40 minutes only (drug, F=4.23 P=.04; 
time, F=9.31 P<.001; drug x time, F=6.89 P<.001). Berman et al5 found Ketamine to 
produce significantly greater BPRS scores, especially the positive symptoms, but 
returned to baseline at 120 minutes (Figure II and Figure IV).  
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DISCUSSION 
 This systematic review of literature showed that low dose Ketamine does decrease 
depressive symptoms when compared to placebo. Zarate et al10 and Berman et al5 both 
showed a significant decrease in HDRS scores over time when compared to placebo. 
When Zarate et al10 examined the HDRS results they showed a large F value (a statistical 
figure found by calculating the difference in the means of the Ketamine versus the 
placebo divided by the standard deviation) with a significant p value from 110 minutes 
through 7 days. The Berman et al5 study revealed a significant mean change in HDRS 
scores from 240 minutes through three days.  
 Zarate et al10 and Berman et al5 studies were both downgraded to low quality 
according to the GRADE approach, due to small sample size and the psychotomimetic 
effects of the medication introducing bias in a crossover style study. Although the 
Ketamine dose was low, patients may be able to discern drug versus placebo based on 
perceptual disturbances with administration of Ketamine, which would subsequently limit 
blinding and potentiate confounding results.  With that being said, the time of onset, and 
peak antidepressant results were similar for all patients, receiving Ketimine, in both 
studies. This  pattern seen across the board is suggestive of a relationship between 
NMDA blockade and antidepressant effects.  
 Misinterpretation between positive change in mood and the side effect of 
euphoria is of concern when studying the efficacy of Ketamine, a known euphorigenic 
drug, in treating depression. This paired with the subjectivity of the rating scales could 
potentially decrease the validity of the results. To combat this Zarate et al10 and Berman 
et al5 both used the BPRS positive symptoms scores to illustrate any connection between 
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the immediate side effects of the medication and the longer antidepressant effects. In both 
studies the improvement in depressive symptoms seen did not correlate to the Ketamine 
induced “high,” this is illustrated in Figure II and IV. The BPRS score peaked at around 
40 minutes in the Zarate et al10 study and at around 60 minutes in the Berman et al5 study 
and abruptly dropped to baseline shortly thereafter, whereas the HDRS scores in both 
studies continued to decrease over the following days.   
In future studies it will be important to us multiple doses and infusion rates to 
determine if there is a dose related effect and the role, if any, of the opiate induced “high” 
felt with Ketamine infusion. It would be of great benefit to use a placebo that has similar 
side effects to those of Ketamine. Utilization of a dopamine agonist as the placebo, may 
be fraught with ethical issues, but would be optimal to decrease bias. Employing a drug 
with similar psychotomimetic effects would also help reduce loss to follow-up due to the 
decrease awareness of placebo versus control.  
Although the results seen in both studies were robust, there are some serious 
limitations in methodology and precision of the studies making utilization of this 
information clinically of little use without further investigation. The adverse 
psychotomimetic effects and abuse potential of Ketamine also limit the use of this drug as 
a mainstay therapy for treating depression. With a large number of NMDA antagonist 
medications on the market, it would also be clinically beneficial to study other similar 
medications that have less perceptual disturbances and are more selective for the NMDA 
receptor.  
 - 16 -  
CONCLUSION 
Although current studies are small the results are promising that there is a role for 
these drugs in treating Major Depressive Disorder. Time will need to be taken, in the 
future, to develop a study that eliminates the confounders and enrolls a larger number of 
participants. As more large randomized control trials are done the use of Ketamine and 
other N-methyl-D-aspartate antagonists will become more apparent.  
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Table I. Characteristics of Reviewed Studies 
*Not fully concealed due to side effects of Ketamine versus placebo  
** 5 lost from therapy group after phase 1, 1 lost from placebo group after phase 1 
*** 1 lost from both placebo and therapy after phase 1 
 
 
Figures I: Review of Literature 
 
 
Designs Limitations Inconsistancy Indirectness Imprecision Other considerations Quality # Participants at Start # Completed Study
Zarate et al10: A Randomized Trial of an NMDA Antagonist in Treatment Resistant Major Depression
RCT concealment * None None None None Low 18 12**
Berman et al5: Antidepressant Effects of Ketamine in Depressed Patients 
RCT concealment * None None None None Low 9 7***
Quality Assessment
223 relevant articles were found by searching 
MEDLINE, Cinahl, and PsychInfo  
209 of the articles were either not 
relevant articles or repeat articles 
14 article were printed for formal 
review 
12 studies did not 
meet 
inclusion/exclusion 
criteria 
2 studies 
remained after an 
exhaustive 
systematic review 
of literature 
2 studies were 
found from the 
bibliographies 
from the 
printed studies 
Neither of the 2 
studies met 
inclusion/exclusion 
criteria 
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Figure II: Zarate et al Ketamine vs Placebo 
 
Figure II: Shows the curve that best describes the relationship between the expected and 
observed outcome, using least square means of the completers using 3 of the depression 
scales. *indicates p<.05; †,  p<.01; ‡,  p<.001 
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Figure III: Zarate et al Responders and Remitters 
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Figure IV: Berman et al Ketamine vs Placebo 
 
 
 Mean changes (± SEM) from baseline in the 25-item Hamilton Depression Rating Scale scores (ΔHDRS), 
the mean Visual Analog Scale “high” scores (VAS-high), and mean positive symptom scores of the Brief 
Psychiatric Rating Scale (BPRS-positive) after ketamine (.5 mg/kg over 40 min) and saline infusions in 
seven subjects completing both treatment conditions. Omission of error bars signifies lack of variance. Post 
hoc contrasts represent comparison to baseline (# signifies p < .05; ##, p ≤ .01; ###, p ≤ .001) or between 
groups (∗, p < .05; ∗∗, p ≤ .01; ∗∗∗p ≤ .001). The former statistic utilized absolute HDRS scores for the top 
panel. These contrasts were performed with Huyn-Felt adjustments for lack of sphericity. Treatment-by-
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time effects on the repeated measures analysis of variance were significant for HDRS (p = .02) and VAS 
scores (p < .001), but not for BPRS-positive symptoms scores (p = .07). 
 
Appendix A 
Hamilton Depression Rating Scale  
 
[Measure redacted from online copy of manuscript] 
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Appendix B 
Young Mania Rating Scale 
 
[Measure redacted from online copy of manuscript] 
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Appendix C 
Beck’s Depression Inventory 
 
 
[Measure redacted from online copy of manuscript] 
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Appendix D  
Brief Psychiatric Rating Scale (BPRS) 
 
[Measure redacted from online copy of manuscript] 
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